The incorporation of high- and low-JAK2V617F mutation status divides PMF patients into two groups: patients with either high JAK2V617F allele burden, mutated CALR, or mutated MPL had a median survival of 104 months (95%CI: 86122 months), whereas patients with low JAK2V617F allele burden or triple-negative mutation
What is a JAK2 blood test for?
JAK2 mutation should not be present in the normal population; it is a sign of a hematologic condition but not specific. It is more common in patients with polycythemia vera or myelofibrosis but also can be seen in those with myelodysplastic syndromes (MDS) and leukemias.
What is the life expectancy of a person with JAK2?
The JAK2 protein is especially important for controlling the production of blood cells from hematopoietic stem cells. These stem cells are located within the bone marrow and have the potential to develop into red blood cells, white blood cells, and platelets.
What does it mean to be JAK2 positive?
The JAK2 mutation test may be used, along with other tests such as erythropoietin, to help diagnose bone marrow disorders that lead to overproduction of blood cells. These conditions are known as myeloproliferative neoplasms (MPNs).
Related Searches
JAK2 V617F mutation positive meansDoes JAK2 positive mean cancerJAK2 exon 12 mutation symptomsJAK2 exon 12 mutation-positiveJAK2 mutationJAK2 V617F mutation negative meaningJAK2 exon 12 mutation negativeJAK2 gene full form
Related links
The JAK2 V617F somatic mutation, mortality and cancer
by C Nielsen 2010 Cited by 157 The JAK2 V617F mutation is an acquired, somatic mutation present in the majority of patients with myeloproliferative cancer (myeloproliferative neoplasms) i.e.
This document is believed to be complete and accurate at the time of publication. In no event shall QIAGEN be liable for incidental, special, multiple, or
JAK2 associates with the cytoplasmic regions of numerous cytokine receptors including those for growth hormone, erythropoietin, leptin, interferon gamma,
This site uses cookies to enhance site navigation and personalize your experience.
By using this site you agree to our use of cookies as described in our Privacy Notice.
You can modify your selections by visiting our Cookie and Advertising Notice.... Read more...Read less
